117 related articles for article (PubMed ID: 28259752)
1. Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models.
Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Pandey AB; Shivachandra SB
Antiviral Res; 2017 May; 141():174-178. PubMed ID: 28259752
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models.
Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Shivachandra SB
Antiviral Res; 2016 Feb; 126():108-16. PubMed ID: 26723250
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis and immunogenicity of recombinant major envelope protein (rA27L) of buffalopox virus, a zoonotic Indian vaccinia-like virus.
Kumar A; Yogisharadhya R; Bhanuprakash V; Venkatesan G; Shivachandra SB
Vaccine; 2015 Oct; 33(41):5396-5405. PubMed ID: 26319070
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
[TBL] [Abstract][Full Text] [Related]
6. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
8. Protective immune response against newly emerging goose tembusu virus infection induced by immunization with a recombinant envelope protein.
Zhao D; Huang X; Han K; Liu Y; Yang J; Liu Q; An F; Li Y
Lett Appl Microbiol; 2015 Oct; 61(4):318-24. PubMed ID: 26108865
[TBL] [Abstract][Full Text] [Related]
9. Enhanced protective immune response to PCV2 subunit vaccine by co-administration of recombinant porcine IFN-γ in mice.
Wang YP; Liu D; Guo LJ; Tang QH; Wei YW; Wu HL; Liu JB; Li SB; Huang LP; Liu CM
Vaccine; 2013 Jan; 31(5):833-8. PubMed ID: 23219694
[TBL] [Abstract][Full Text] [Related]
10. A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen.
Hunt AR; Cropp CB; Chang GJ
J Virol Methods; 2001 Sep; 97(1-2):133-49. PubMed ID: 11483224
[TBL] [Abstract][Full Text] [Related]
11. Yeast expressed classical swine fever E2 subunit vaccine candidate provides complete protection against lethal challenge infection and prevents horizontal virus transmission.
Lin GJ; Deng MC; Chen ZW; Liu TY; Wu CW; Cheng CY; Chien MS; Huang C
Vaccine; 2012 Mar; 30(13):2336-41. PubMed ID: 22300723
[TBL] [Abstract][Full Text] [Related]
12. A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
Diamos AG; Pardhe MD; Sun H; Hunter JGL; Kilbourne J; Chen Q; Mason HS
Front Immunol; 2020; 11():576012. PubMed ID: 33343565
[TBL] [Abstract][Full Text] [Related]
13. Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection.
Qu P; Zhang W; Li D; Zhang C; Liu Q; Zhang X; Wang X; Dai W; Xu Y; Leng Q; Zhong J; Jin X; Huang Z
Antiviral Res; 2018 Jun; 154():97-103. PubMed ID: 29665376
[TBL] [Abstract][Full Text] [Related]
14. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
15. The bovine viral diarrhea virus E2 protein formulated with a novel adjuvant induces strong, balanced immune responses and provides protection from viral challenge in cattle.
Snider M; Garg R; Brownlie R; van den Hurk JV; van Drunen Littel-van den Hurk S
Vaccine; 2014 Nov; 32(50):6758-64. PubMed ID: 25454860
[TBL] [Abstract][Full Text] [Related]
16. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474
[TBL] [Abstract][Full Text] [Related]
17. A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge.
Mucker EM; Golden JW; Hammerbeck CD; Kishimori JM; Royals M; Joselyn MD; Ballantyne J; Nalca A; Hooper JW
J Virol; 2022 Feb; 96(3):e0150421. PubMed ID: 34851148
[TBL] [Abstract][Full Text] [Related]
18. Development of an APC-targeted multivalent E2-based vaccine against Bovine Viral Diarrhea Virus types 1 and 2.
Pecora A; Malacari DA; Perez Aguirreburualde MS; Bellido D; Nuñez MC; Dus Santos MJ; Escribano JM; Wigdorovitz A
Vaccine; 2015 Sep; 33(39):5163-71. PubMed ID: 26279338
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
[TBL] [Abstract][Full Text] [Related]
20. Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres.
Brandhonneur N; Loizel C; Chevanne F; Wakeley P; Jestin A; Le Potier MF; Le Corre P
Int J Pharm; 2009 May; 373(1-2):16-23. PubMed ID: 19429284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
